Slowing Kidney Disease

NNH Clinical Protocol

Slowing Kidney Disease

Small changes today can move dialysis years into the future.

Developed by Craig G. Hurwitz, MD

📚 Patient Educator📄 Evidence-based, not predictive⚠️ From Northern Nephrology & Hypertension

Step 1

[Picker step title — e.g. Select the procedure / Select the indication]

[One sentence guiding the clinician on what they're choosing.]

[OPTION_1_TITLE][short tag][OPTION_2_TITLE][short tag][OPTION_3_TITLE][short tag][OPTION_4_TITLE][short tag][OPTION_5_TITLE][short tag][OPTION_6_TITLE][short tag]

Recommendation

—

Choose a different procedure

This tool is educational and not intended to predict individual outcomes. Verify allergies, drug interactions, and renal/hepatic dose adjustments before administration. [Replace this sentence with protocol-appropriate caveats about evidence quality, regulatory grade, or guideline limitations.]

Reference

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314.

Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease (DAPA-CKD). N Engl J Med. 2020;383(15):1436-1446. Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes (FIDELIO-DKD). N Engl J Med. 2020;383(23):2219-2229.

Kidney care starts here!

Call: 518-324-4000

Patient Portal

Slowing Kidney Disease

Slowing Kidney Disease

[Picker step title — e.g. Select the procedure / Select the indication]

—

Reference

For Patients

For Professionals

For NNH Staff

Main Office

Office Hours: Mon-Fri 9AM-5PM

© 2026 Craig G. Hurwitz, MD — Northern Nephrology & Hypertension